Ginkgo Bioworks
DNA
Ginkgo Bioworks (DNA) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| TD Cowen | Downgraded | Buy → Hold | $9.00 from $12.00 | Aug 7, 2026 |
| BTIG | Maintained | Sell | $5.00 from $9.00 | Mar 12, 2026 |
| TD Cowen | Maintained | Buy | $12.00 from $14.00 | Jan 8, 2026 |
| BTIG | Maintained | Sell | $9.00 from $6.00 | Aug 25, 2025 |
| TD Cowen | Maintained | Buy | $10.00 from $3.00 | Sep 20, 2024 |
| BTIG | Maintained | Sell | $7.00 from $0.20 | Aug 23, 2024 |
| Goldman Sachs | Maintained | Sell | $0.30 from $0.80 | Jul 9, 2024 |
| BTIG | Maintained | Sell | $0.20 from $0.50 | Jun 26, 2024 |
| Morgan Stanley | Maintained | Equal-Weight | $1.00 from $2.00 | May 15, 2024 |
| BTIG | Downgraded | Neutral → Sell | — | May 15, 2024 |
| William Blair | Downgraded | Market Perform → Underperform | — | May 10, 2024 |
| TD Cowen | Maintained | Outperform | $3.00 from $7.00 | Mar 1, 2024 |
| Goldman Sachs | Maintained | Sell | $1.10 from $1.25 | Jan 23, 2024 |
| Goldman Sachs | Maintained | Sell | $1.10 from $1.25 | Jan 22, 2024 |
| Raymond James | Downgraded | Outperform → Market Perform | $2.50 | Nov 15, 2023 |
| Raymond James | Downgraded | Outperform → Market Perform | $2.50 | Nov 14, 2023 |
| BTIG | Downgraded | Buy → Neutral | — | Nov 9, 2023 |
| Goldman Sachs | Maintained | Sell | $1.25 from $3.00 | Jun 5, 2023 |
| Goldman Sachs | Downgraded | Neutral → Sell | $1.25 from $3.00 | Jun 2, 2023 |
| William Blair | Downgraded | Outperform → Market Perform | — | May 11, 2023 |
Frequently asked questions
What is the latest analyst rating on DNA?
On Aug 7, 2026, TD Cowen downgraded Ginkgo Bioworks to Hold with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.